# A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma

> **NCT00431912** · PHASE2 · COMPLETED · sponsor: **Valerio Therapeutics** · enrollment: 25 (actual)

## Conditions studied

- Cutaneous T-cell Lymphoma

## Interventions

- **DRUG:** APO866

## Key facts

- **NCT ID:** NCT00431912
- **Lead sponsor:** Valerio Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2011-01
- **Final completion:** 2011-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2015-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00431912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00431912, "A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00431912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*